This past week was a wacky and wild one for the stem cell field. All kinds of crazy things happened all in one week. What does it all mean? Stem cells the new steroids for sports? Reports surface this week that NY Yankees pitcher Bartolo Colon, had received a non-FDA approved stem cell treatment for …
A crazy week for stem cells: what the heck does it all mean? Read More »
There are a lot of myths in the stem cell field, some even embraced by some stem cell scientists such as the notion that teratoma are always benign. But when we start talking about translating stem cell technology into the clinic, to the bedside, it is especially important to cast aside our myths, no …
Myth of Perfect Stem Cell: meaning for ACT, Geron and field Read More »
Who’s who in the iPS cell field? In this post, I examine the people, journals, places, funding agencies, and companies that are the leaders in the iPS cell field. I start with publishing. Last year we did a post on publishing trends in the iPS cell field. It suggested that the iPS cell field was exploding …
Who’s who in iPS cells: scientists, journals, funding agencies, countries, and biotechs Read More »
What are iPS cells? We talk about iPS cells all the time. We are very excited about them. Heck, the web address for this blog is ipscell.com. But what are iPS cells, really? A simple definition of iPS cells is the following: Embryonic stem cell-like cells that are made from non-stem cells in a lab. …
Advanced Cell Technology (ACT) announced that the FDA has approved their second human ES cell-based clinical trial, a combined Phase I/II, for the treatment of blindness. As a result, soon ACT will have two active, human ES cell-based clinical trials, both using the same human ES cell-based drug. The aim of the 2nd trial is …
FDA approves ACT’s second stem cell trial for blindness Read More »
Cancer patients and their doctors face daunting challenges at the time of diagnosis. Many crucial questions either cannot be answered or rely upon relatively low-tech methods whose accuracy is far from ideal. For example, how aggressive is this tumor? Has it already spread? After diagnosis and initial treatment, it is critical to monitor patients for …
One in a billion: finding stray cancer stem cells Read More »
As the year comes to a close this week, it is a good time to look back on 2010 and consider the major events in the stem cell field and give out awards. Stem Cell Event of the Year. I would give this award as a dual prize to Geron and Advanced Cell Technology (ACT) …
It has been a rollercoaster few months between the anti-hESC court cases as well as Geron and Advanced Cell Technology (ACT) receiving the OK from the FDA to proceed with initial clinical trials of stem cell treatments. It’s OK to be excited about the clinical trials and I for one am, but we have to …
Challenges translating stem cell treatments to patients Read More »
If IPS cells are not ready for prime time, it is probably due to these three critical challenges for these amazing cells. TUMORIGENICITY Those of us who work with IPS cells are very excited about their potential for use in regenerative medicine therapies. One serious hurdle we have talked about in the past is tumorigenicity. …
Not ready for prime time: the three critical challenges for IPS cells Read More »
Cancer is a class of diseases that are intimately linked to stem cells. In fact, I would go so far as to call some types of cancer cells and stem cells, cousins. This concept, of a tight relationship between stem and cancer cells, is under intense investigation but at the same time it is something …